Allergy Therapeutics posts maiden full-year profit and plans expansion
This article was originally published in Scrip
Allergy Therapeutics has reported its first profitable full-year results for the 12 months ended June 30, 2010. Having "turned the corner" on its financial performance, the UK-based firm will continue to use its "stronger P&L (profit and loss) position as a platform for growth", it told Scrip.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.